Turn Therapeutics Inc. — Form 8-K
Filed September 10, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Turn Therapeutics announced that CEO Bradley Burnam and Chief Clinical/Regulatory Officer Dr. Stephen Hahn will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23, 2026 at 1:30 PM ET. The presentation will detail the company's atopic dermatitis clinical program, including stage 2 enrichment strategy findings in moderate-severe pruritus patients and a cohort with lower EASI scores but high disease severity. A webcast will be available on the company's investor relations website with a six-month replay.
Why this rating
Routine investor presentation announcement; no financial data, partnerships, or clinical trial results disclosed; standard conference participation.
See more from September 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.